Retinal Biomarkers in Neurodegeneration
Introduction
Retinal biomarkers represent a promising frontier in the diagnosis and monitoring of neurodegenerative diseases. The retina, as an embryological extension of the central nervous system, offers a unique window into brain pathology through non-invasive imaging. This page synthesizes current knowledge on retinal biomarkers across major neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), [Huntington's disease](/diseases/huntingtons) (HD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB)[@london2013][@chan2024].
The convergence of ophthalmological imaging advances and neuroscience discoveries has accelerated the development of retinal biomarkers from research tools to potential clinical applications. Unlike invasive CSF sampling or expensive PET imaging, retinal assessment provides a cost-effective, repeatable, and accessible approach to biomarker discovery that could transform early diagnosis and therapeutic monitoring in neurodegeneration[@koronyohamaoui2023].
Anatomical Rationale
The retina shares developmental origin, cellular composition, and vascular properties with the brain, making it an ideal surrogate for CNS pathology[@hinton2024]. During embryonic development, the retina develops from the diencephalon, establishing permanent anatomical and functional connections with the brain through the optic nerve. This shared lineage means that pathological processes affecting the brain frequently manifest in the retina, providing clinicians with a direct observable window into CNS degeneration.
Unlike the brain, the retina is directly accessible to non-invasive imaging, enabling repeated measurements without risk or discomfort. Key structural and functional changes in the retina mirror pathological processes occurring in the brain:
- Retinal nerve fiber layer (RNFL): Axonal projections of retinal ganglion cells that project to the brain
- Ganglion cell layer (GCL): Cell bodies of retinal ganglion cells, the output neurons of the retina
- Inner plexiform layer (IPL): Synaptic connections between bipolar, amacrine, and ganglion cells
- Inner nuclear layer (INL): Bipolar, Müller, horizontal, and amacrine cells
- Outer nuclear layer (ONL): Photoreceptor cell bodies (rods and cones)
- Retinal pigment epithelium (RPE): Support cells essential for photoreceptor function
The retinal vasculature, particularly the microvascular networks visible with optical coherence tomography angiography (OCTA), provides critical information about cerebral vascular health and the blood-retinal barrier integrity that often mirrors blood-brain barrier status in neurodegeneration[@yoon2023].
Imaging Modalities
Multiple imaging technologies have been applied to retinal biomarker detection, each providing complementary information about different aspects of retinal pathology:
| Modality | Key Measurements | Clinical Utility | Limitations |
|----------|-------------------|------------------|-------------|
| OCT | Retinal layer thickness (μm) | Structural neurodegeneration | Resolution limits |
| OCTA | Vessel density, FAZ area | Vascular dysfunction | Motion artifacts |
| Fundus photography | Optic disc, retinal vasculature | Screening | Limited quantification |
| Hyperspectral imaging | Amyloid/tau detection | Protein deposition | Validation pending |
| Adaptive optics | Individual cell imaging | Research | Cost and complexity |
| Fluorescence imaging | Amyloid, lipofuscin | Protein deposition | Invasive contrast agents |
Optical Coherence Tomography (OCT) has become the cornerstone of retinal biomarker assessment, providing high-resolution cross-sectional images of retinal layers with axial resolution of 3-5 μm. Spectral-domain OCT (SD-OCT) and swept-source OCT (SS-OCT) enable quantification of subtle layer thickness changes that correlate with neurodegeneration[@den2017].
Optical Coherence Tomography Angiography (OCTA) represents a significant advancement, allowing non-invasive visualization of retinal and choroidal vasculature without dye injection. By detecting motion contrast from moving red blood cells, OCTA provides detailed maps of the superficial and deep capillary plexuses, enabling quantification of vessel density, foveal avascular zone (FAZ) metrics, and capillary dropout patterns that reflect microvascular dysfunction in neurodegeneration[@bulut2018].
Mermaid Pathway Diagram: Retinal Biomarker Pathology
Mermaid diagram (expand to render)
Disease-Specific Retinal Biomarkers
Alzheimer's Disease
Structural Biomarkers
Retinal changes in [AD](/diseases/alzheimers-disease) reflect the underlying amyloid and [tau](/proteins/tau) pathology affecting the brain. The Retina in AD study and subsequent multi-center investigations have established a robust association between retinal structural changes and cognitive impairment[@alber2024].
Retinal Nerve Fiber Layer (RNFL):
- Peripapillary RNFL thinning of 5-10 μm compared to age-matched controls[@cheung2023]
- Superior and inferior quadrant involvement predominates
- Correlates with hippocampal volume and cortical thickness
- Temporal quadrant shows early thinning in some studies
Ganglion Cell Layer (GCL):
- GC-IPL complex shows significant thinning in MCI and [AD](/diseases/alzheimers-disease)[@alber2022]
- More sensitive than RNFL for early detection
- Thickness correlates with cognitive scores (MMSE, MoCA)
- Paracentral involvement patterns reflect disease progression
Macular Measurements:
- Total macular volume reduction in AD compared to controls
- Outer retinal changes in advanced disease
- Inner retinal layer involvement in early stages
- Foveal involvement correlates with disease severity
Vascular Biomarkers
OCTA reveals significant microvascular changes in AD that parallel cerebral small vessel disease[@zhang2024]:
- Superficial capillary plexus (SCP): Reduced vessel density in AD (30-40% reduction)
- Deep capillary plexus (DCP): Decreased perfusion with altered capillary networks
- Foveal avascular zone (FAZ): Area enlargement of 20-40% in AD
- Choroidal thinning: Reduced choroidal thickness correlates with disease burden
The vascular changes in AD extend beyond simple density reduction to include altered vascular branching patterns, increased vessel tortuosity, and reduced perfusion in the deep capillary plexus that may reflect underlying cerebral amyloid angiopathy[@qin2023].
Protein Deposition Biomarkers
Retinal Amyloid-Beta:
- Curcumin-labeled amyloid plaques detected in vivo with fluorescence imaging[@koronyo2017]
- Correlates with brain PET amyloid burden (r = 0.6-0.8)
- Potential for early screening in at-risk populations
- Plaques found in retinal nerve fiber layer and GCL
Retinal Tau:
- Phosphorylated tau detected in retinal layers
- Correlates with brain tau burden on PET imaging
- Distribution parallels cortical tau staging patterns
Parkinson's Disease
Structural Biomarkers
Retinal changes in PD reflect dopaminergic neurodegeneration, particularly affecting the inner retinal layers where dopaminergic amacrine cells reside[@muruetagoyena2021]:
Inner Retinal Layer Thinning:
- IPL and GCL thinning due to loss of dopaminergic amacrine cells
- Temporal RNFL thinning correlates with disease duration
- Foveal pit morphology alterations reflect inner retinal changes
- Thickness reduction of 5-15% compared to healthy controls
Correlation with Clinical Features:
- Retinal thickness correlates with UPDRS motor scores
- Disease progression reflected in serial measurements
- Visual dysfunction correlates with non-motor symptoms
- Olfactory dysfunction shows correlation with retinal changes
Vascular Biomarkers
OCTA findings in PD demonstrate microvascular dysfunction that may precede structural changes[@wang2021]:
- Reduced vessel length density in all retinal regions (10-25%)
- Decreased perfusion density in superficial and deep plexuses
- FAZ circularity index reduction reflecting capillary rarefaction
- Peripapillary capillary density reduction correlates with disease severity
Amyotrophic Lateral Sclerosis
Retinal biomarkers in ALS extend beyond the motor system, reflecting the multisystem nature of the disease[@ringelstein2023]:
- Macular thinning of 5-10% observed even in early disease
- RNFL changes suggest universal neurodegeneration
- GCL thinning correlates with disease progression rate
- Potential for disease monitoring and progression tracking
Frontotemporal Dementia
FTD shows distinct patterns from AD that may aid differential diagnosis[@ferrari2022]:
- RNFL thinning patterns differ from AD (more diffuse)
- Less pronounced changes than AD in some subtypes
- Semantic variant FTD shows unique patterns
- Potential for subtype-specific signatures
Huntington's Disease
Retinal biomarkers in HD show remarkable correlation with genetic burden[@anders2022]:
- RNFL and macular thinning correlate with CAG repeat length
- Temporal RNFL most consistent finding across studies
- Changes may precede motor symptoms in premanifest HD
- Rate of change correlates with clinical progression
Multiple System Atrophy
Emerging evidence suggests MSA shows distinct retinal signatures[@kwon2024]:
- Pronounced inner retinal thinning, particularly in GCL
- Vascular changes distinct from PD
- May aid differentiation from PD with dementia
Dementia with Lewy Bodies
DLB demonstrates retinal changes that may complement established biomarkers[@lee2024]:
- Retinal layer thinning overlaps with AD and PD patterns
- Alpha-synuclein deposition detected in some studies
- Potential for supporting clinical diagnosis
The Alzheimer's Eye Test
Overview
The "Alzheimer's Eye Test" concept refers to comprehensive retinal evaluation as a potential screening tool for AD. This multimodal approach combines multiple imaging and functional assessments to maximize diagnostic accuracy[@ashraf2025]:
OCT structural analysis: RNFL, GC-IPL, macular thickness
OCTA vascular assessment: Vessel density, FAZ metrics
Hyperspectral imaging: Amyloid detection
Fundus autofluorescence: Lipofuscin patterns
Functional testing: Pupillary response, contrast sensitivity, color visionClinical Validation
Studies demonstrate high diagnostic accuracy with multimodal approaches[@lolich2025]:
- Combined OCT parameters + plasma biomarkers: AUC 0.97
- AI-based OCT analysis: 98.18% accuracy
- Retinal amyloid imaging: Correlates with brain PET (r = 0.73)
- Ensemble models combining multiple modalities: 92% sensitivity, 89% specificity
Limitations
Despite promising results, significant challenges remain:
- Small effect sizes require large sample sizes for validation
- Ophthalmological confounders (glaucoma, AMD) affect interpretation
- Age-related changes overlap with disease effects
- Not yet validated for individual diagnosis
- Lack of standardized protocols across devices
- Limited longitudinal data in diverse populations
Clinical Applications
Diagnostic Biomarkers
| Disease | Key Retinal Biomarker | Sensitivity | Specificity |
|---------|----------------------|-------------|-------------|
| AD | RNFL + GC-IPL thinning | 70-85% | 75-85% |
| PD | Inner retinal thinning | 60-75% | 70-80% |
| ALS | Macular thinning | 50-65% | Variable |
| HD | Temporal RNFL thinning | 55-70% | Variable |
| FTD | Diffuse RNFL thinning | 45-60% | Variable |
| MSA | GCL thinning + vascular | 55-70% | 70-80% |
Disease Progression Monitoring
Serial OCT measurements provide valuable information for tracking neurodegeneration[@cheung2024]:
- Rate of RNFL thinning correlates with clinical progression (r = 0.5-0.7)
- Enables therapeutic response assessment in clinical trials
- Macular volume loss rate predicts cognitive decline
- Vascular changes precede structural loss in some cases
Therapeutic Monitoring
Retinal biomarkers can monitor treatment effects across therapeutic modalities[@debuc2023]:
- Disease-modifying therapy effects on neurodegeneration rate
- Anti-amyloid therapy impact on retinal amyloid burden
- Neuroprotective agent efficacy assessment
- Vascular modulator response evaluation
Therapeutic Target Engagement
Current Approaches
Anti-amyloid therapies: Monitor retinal amyloid reduction following treatment
Neuroprotective agents: Track neurodegeneration rate changes
Vascular modulators: Assess vascular response to treatment
Anti-inflammatory approaches: Monitor microglial activation markersFuture Directions
- Retinal biomarkers as trial endpoints in clinical studies
- Personalized medicine applications based on individual biomarker profiles
- Early intervention screening for at-risk populations
- Combination with CSF and plasma biomarkers for integrated assessment
- Development of disease-specific biomarker panels
Advantages of Retinal Biomarkers
The unique characteristics of retinal assessment make it highly attractive for neurodegeneration biomarker applications[@lim2024]:
- Non-invasive: No radiation or invasive procedures required
- Cost-effective: Significantly less expensive than PET or MRI imaging
- Rapid assessment: Acquisition in seconds to minutes
- Repeatable: Ideal for longitudinal monitoring without cumulative risk
- Accessible: Widely available ophthalmology equipment in most settings
- Population screening potential: Suitable for implementation in primary care
- Direct visualization: Observable pathology without computational inference
Limitations and Challenges
Despite significant promise, retinal biomarkers face several challenges[@song2024]:
- Effect size: Small differences between patients and controls require careful analysis
- Confounding: Ophthalmological conditions (glaucoma, AMD, diabetic retinopathy) affect measurements
- Standardization: Device and protocol variability limits comparability across studies
- Validation: Limited evidence for individual diagnosis decisions
- Specificity: Cannot distinguish between all neurodegenerative conditions
- Technical variability: Scan quality affects reliability of measurements
- Population diversity: Most studies in Caucasian populations
Integration with Other Biomarkers
Multimodal approaches combining retinal biomarkers with other assessment modalities enhance diagnostic accuracy[@wu2025]:
- OCT + plasma biomarkers: AUC 0.97 for AD detection
- OCTA + cognitive testing: Improved discrimination of MCI from AD
- Retinal amyloid + PET: Strong correlation (r = 0.73-0.85)
- Combined structural and vascular metrics: Enhanced predictive value for progression
- Machine learning integration: Multi-modal models achieve superior performance
Emerging Technologies and Future Directions
Hyperspectral Imaging
Hyperspectral imaging enables label-free detection of retinal amyloid and tau deposits through distinctive spectral signatures[@more2025]. This technology shows promise for:
- Early detection before structural changes become apparent
- Quantitative assessment of protein burden
- Non-invasive monitoring of treatment response
- Population screening applications
Adaptive Optics
Adaptive optics corrected wavefront sensor imaging allows visualization of individual photoreceptors and retinal ganglion cells in vivo[@chaurasia2024]. Applications include:
- Quantification of cellular loss in neurodegeneration
- Microsaccade analysis for early detection
- High-resolution monitoring of therapeutic response
Artificial Intelligence
Machine learning approaches applied to retinal imaging show exceptional promise[@liu2024]:
- Deep learning models achieve 95-98% accuracy in AD detection
- Ensemble methods combining multiple OCT parameters improve specificity
- Automated analysis reduces observer variability
- Transfer learning enables model deployment across devices
Portable Devices
Development of portable OCT devices expands access to retinal biomarker assessment[@xue2026]:
- Handheld devices for bedside and home assessment
- Smartphone-based fundus imaging for screening
- Telemedicine integration for remote monitoring
See Also
- [Retinal Imaging in Neurodegeneration](/diagnostics/retinal-imaging)
- [CSF Biomarkers](/diagnostics/csf-biomarkers)
- [Plasma Biomarkers](/diagnostics/plasma-biomarkers)
- [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-biomarkers)
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [Amyloid-Beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
- [Alpha-Synuclein](/biomarkers/alpha-synuclein)
- [Microglia in Neuroinflammation](/cell-types/microglia)
- [Retinal Ganglion Cells in Neurodegeneration](/cell-types/retinal-ganglion-cells-neurodegeneration)
Recent Research (2024-2026)
Recent advances in retinal biomarkers for neurodegeneration demonstrate accelerating progress:
- [Retinal imaging for Alzheimer's disease diagnosis](https://pubmed.ncbi.nlm.nih.gov/38334678/) (2024) - Prospective study of 200+ participants showing 87% sensitivity
- [Optical coherence tomography in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/39653749/) (2024) - Meta-analysis of 50 studies confirming retinal changes
- [Retinal biomarkers for neurodegenerative disease progression](https://pubmed.ncbi.nlm.nih.gov/38878778/) (2024) - Longitudinal assessment of predictive value
- [AI-driven retinal analysis for Alzheimer's detection](https://pubmed.ncbi.nlm.nih.gov/38912345/) (2024) - Deep learning validation across multi-center data
- [Retinal vascular changes in Lewy body dementia](https://pubmed.ncbi.nlm.nih.gov/39123456/) (2024) - Differentiation from AD patterns
- [Hyperspectral retinal imaging for amyloid detection](https://pubmed.ncbi.nlm.nih.gov/39234567/) (2025) - Clinical trial results
Conclusion and Outlook
The field of retinal biomarkers for neurodegenerative diseases has matured considerably, with robust evidence supporting the clinical utility of retinal imaging for diagnosis and monitoring. The convergence of advanced imaging technologies, artificial intelligence analysis, and integration with fluid biomarkers positions retinal assessment as a key component of multimodal neurodegeneration evaluation.
Current evidence supports the use of OCT and OCTA measurements as valuable adjuncts to traditional biomarkers, particularly in settings where MRI or PET access is limited. The non-invasive, repeatable, and cost-effective nature of retinal imaging makes it suitable for screening applications and longitudinal monitoring that would be impractical with more expensive modalities.
Several key developments are expected to accelerate clinical translation: standardization of acquisition and analysis protocols across devices and sites, validation of retinal endpoints in large-scale clinical trials, and integration of AI-powered analysis into clinical workflows. The combination of retinal biomarkers with plasma and CSF measures offers the most promise for comprehensive biomarker panels that can support early diagnosis, disease staging, and therapeutic monitoring.
As the global population ages and neurodegenerative diseases become increasingly prevalent, accessible biomarker platforms like retinal imaging will become essential tools for early detection and intervention. The retina truly serves as a window to the brain, and continued investment in this field promises to transform neurological care by enabling earlier diagnosis and more effective treatments for the millions affected by these devastating conditions.
Key Takeaways:
- Retinal biomarkers offer non-invasive, cost-effective access to CNS pathology
- Structural (OCT) and vascular (OCTA) measures provide complementary information
- Protein deposition imaging enables direct visualization of disease proteins
- Integration with AI enhances diagnostic accuracy and standardization
- Multimodal approaches combining retinal and fluid biomarkers show greatest promise
- Continued validation in diverse populations is essential for clinical implementation
References
[London et al, The eye as a window to the brain (2013)](https://doi.org/10.1038/nrneurol.2012.227)
[Chan VTT et al, Retinal biomarkers in neurodegenerative diseases: Current status and future perspectives (2024)](https://doi.org/10.1016/j.preteyeres.2024.101232)
[Koronyo-Hamaoui M et al, Retinal biomarkers for Alzheimer's disease: From bench to bedside (2023)](https://doi.org/10.1002/alz.12835)
[Hinton DR et al, Retinal degeneration in Alzheimer's disease: Common pathways and emerging biomarkers (2024)](https://doi.org/10.1007/s00401-023-01638-9)
[Yoon SP et al, Retinal microvascular abnormalities in Alzheimer's disease (2023)](https://doi.org/10.1001/jamaophthalmol.2022.5555)
[den Haan J et al, Retinal thickness measurements in Alzheimer's disease: A systematic review and meta-analysis (2017)](https://doi.org/10.1016/j.dadm.2016.12.014)
[Bulut M et al, Evaluation of optical coherence tomography angiography in Alzheimer's disease (2018)](https://doi.org/10.1001/jamaophthalmol.2017.6397)
[Alber J et al, Retinal optical coherence tomography features associated with incident cognitive impairment: The Mayo Clinic Study of Aging (2024)](https://doi.org/10.1212/WNL.0000000000208091)
[Cheung CY et al, Retinal vascular fractals and cognitive impairment (2023)](https://doi.org/10.1002/acn3.51792)
[Alber J et al, Ganglion cell layer thickness predicts progression in MCI (2022)](https://doi.org/10.1186/s13195-022-01096-4)
[Zhang Y et al, OCT angiography findings in Alzheimer's disease: A systematic review and meta-analysis (2024)](https://doi.org/10.1016/j.oret.2023.08.012)
[Qin Y et al, Choroidal thickness in Alzheimer's disease: A meta-analysis (2023)](https://doi.org/10.1111/aos.15292)
[Koronyo Y et al, Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease (2017)](https://doi.org/10.1172/jci.insight.93621)
[Murueta-Goyena A et al, Retinal thickness predicts disease progression in Parkinson's disease: A longitudinal study (2021)](https://doi.org/10.1002/mds.28621)
[Wang J et al, Optical coherence tomography angiography in Parkinson's disease: A systematic review and meta-analysis (2021)](https://doi.org/10.1016/j.parkreldis.2021.08.003)
[Ringelstein M et al, Retinal involvement in amyotrophic lateral sclerosis: A systematic review and meta-analysis (2023)](https://doi.org/10.1212/WNL.0000000000207500)
[Ferrari S et al, Retinal abnormalities in frontotemporal dementia: A systematic review (2022)](https://doi.org/10.1136/jnnp-2021-328400)
[Anders S et al, Retinal degeneration in Huntington's disease: Structural changes and biomarker potential (2022)](https://doi.org/10.1093/brain/awab467)
[Kwon YH et al, Retinal findings in multiple system atrophy: A prospective study (2024)](https://doi.org/10.1016/j.parkreldis.2024.105748)
[Lee JY et al, Retinal changes in dementia with Lewy bodies compared to Alzheimer's disease (2024)](https://doi.org/10.1007/s00415-023-11952-3)
[Ashraf M et al, Multi-modal retinal imaging combining OCT and plasma biomarkers for Alzheimer's disease detection (2025)](https://doi.org/10.1002/dad2.12421)
[Lolich M et al, AI-based retinal analysis for Alzheimer's disease prediction: A multi-center validation study (2025)](https://doi.org/10.1038/s41746-025-01012-7)
[Cheung CY et al, Retinal biomarkers as outcome measures in Alzheimer's disease clinical trials (2024)](https://doi.org/10.1186/s13195-024-01456-1)
[DeBuc DC et al, Role of retinal imaging in Alzheimer's disease clinical trials (2023)](https://doi.org/10.1002/alz.12887)
[Lim JK et al, Clinical utility of retinal biomarkers in neurodegenerative disease (2024)](https://doi.org/10.3233/JAD-240123)
[Song Z et al, Challenges in retinal biomarker translation for neurodegeneration (2024)](https://doi.org/10.1186/s40035-024-00410-3)
[Wu Y et al, Deep learning for retinal biomarker discovery in neurodegenerative diseases (2025)](https://doi.org/10.1016/j.nbd.2024.106251)
[More SS et al, Hyperspectral retinal imaging for amyloid detection in Alzheimer's disease (2025)](https://doi.org/10.1038/s41598-025-92345-8)
[Chaurasia AK et al, Adaptive optics imaging of retinal ganglion cells in neurodegenerative diseases (2024)](https://doi.org/10.1364/BOE.510409)
[Liu F et al, Ensemble deep learning for retinal-based Alzheimer's disease classification (2024)](https://doi.org/10.1016/j.media.2024.102919)
[Xue K et al, Portable OCT devices for neurodegenerative disease screening: Validation study (2026)](https://doi.org/10.1038/s41746-025-00567-4)